The United States Food and Drug Administration (FDA) has approved United States-based Blueprint Medicines Corporation's (NASDAQ: BPMC) GAVRETO (pralsetinib) intended for the treatment of patients with RET-altered thyroid cancers, it was reported on Tuesday.
The accelerated approval increases the labelled indications for the product to include adult and paediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer who need systemic therapy, or with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
The product is a once-daily oral precision therapy aimed to potently and selectively target RET alterations that drive multiple tumour types. It is jointly commercialised in the United States by Blueprint Medicines and Genentech, a wholly owned member of the Roche Group, under Blueprint Medicines' collaboration with Roche.
The approval is based on efficacy and safety results from the ARROW trial.
Foresee Pharmaceuticals receives positive CHMP opinion for CAMCEVI 21 mg
Great Novel Therapeutics' GNTbm-38 approved by US FDA for Phase I trial
Johnson & Johnson reports US FDA approval of TECVAYLI plus DARZALEX FASPRO for RRMM
Airiver Medical's Airiver Pulmonary DCB receives US FDA Breakthrough Device Designation
Sanaregen receives FDA clearance for retinal degeneration clinical trial
Esperion to acquire Corstasis, expanding cardiovascular portfolio
ReviR Therapeutics doses first participant in First-in-Human Phase 1 clinical trial of RTX-117
BD receives FDA clearance for Surgiphor 1000mL irrigation system
United Therapeutics' ralinepag reduces risk of clinical worsening in pivotal PAH study
FDA accepts rusfertide NDA and grants priority review for polycythemia vera